Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Saudi Med J ; 42(9): 927-968, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34470833

RESUMEN

The demand for liver transplantation in the Kingdom of Saudi Arabia (KSA) is associated with the country's high burden of liver disease. Trends in the epidemiology of liver transplantation indications among recipients in KSA have changed over 20 years. Non-alcoholic steatohepatitis has eclipsed the hepatitis C virus in the country due to the effective treatment strategies for HCV. Risk factors for NASH, like type 2 diabetes mellitus, obesity, and hyperlipidemia, are becoming a major concern and a leading indication for liver transplantation in the KSA. There is also a significantly increased prevalence and incidence of genetic adult familial liver diseases in KSA. New immunosuppressive agents and preservation solutions, improved surgical capabilities, and early disease recognition and management have increased the success rate of liver transplant outcome but concerns about the side effects of immunosuppressive therapy can jeopardise long-term survival outcomes. Despite this, indications for liver transplantation continue to increase, resulting in ongoing challenges to maximize the number of potential donors and reduce patient mortality rate while expecting to get transplanted. The Saudi Center of Organ Transplant is the recognized National Organ Donation Agency for transplantation, which renders important support for procurement and allocation of organs. This guidance document aims to help healthcare providers in managing patients in the liver transplant setting.


Asunto(s)
Diabetes Mellitus Tipo 2 , Trasplante de Hígado , Obtención de Tejidos y Órganos , Adulto , Humanos , Arabia Saudita/epidemiología , Sociedades Médicas , Donantes de Tejidos
3.
Ann Saudi Med ; 40(4): 273-280, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32564624

RESUMEN

In December 2019, a novel coronavirus was identified in patients in Wuhan, China. The virus, subsequently named severe acute respiratory syndrome coronavirus-2, spread worldwide and the disease (coronavirus disease 2019 or COVID-19) was declared a global pandemic by the World Health Organization in March 2020. Older adults and individuals with comorbidities have been reported as being more vulnerable to COVID-19. Patients with chronic liver disease (CLD) have compromised immune function due to cirrhosis and are more susceptible to infection. However, it is unclear if patients with CLD are more vulnerable to COVID-19 and its complications than other populations. The high number of severe cases of COVID-19 has placed an unusual burden on health systems, compromising their capacity to provide the regular care that patients with CLD require. Hence, it is incredibly crucial at this juncture to provide a set of interim recommendations on the management of patients with CLD during the current COVID-19 outbreak.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Hepatopatías/epidemiología , Neumonía Viral/epidemiología , Adenosina Monofosfato/efectos adversos , Adenosina Monofosfato/análogos & derivados , Corticoesteroides/efectos adversos , Alanina/efectos adversos , Alanina/análogos & derivados , Amidas/efectos adversos , Antivirales/uso terapéutico , Azetidinas/efectos adversos , Betacoronavirus , Biopsia/métodos , COVID-19 , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/terapia , Comorbilidad , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/prevención & control , Combinación de Medicamentos , Interacciones Farmacológicas , Inhibidores Enzimáticos/efectos adversos , Hepatitis Autoinmune/epidemiología , Hepatitis Autoinmune/terapia , Hepatitis Viral Humana/epidemiología , Hepatitis Viral Humana/terapia , Humanos , Hidroxicloroquina/efectos adversos , Inmunosupresores/uso terapéutico , Inhibidores de las Cinasas Janus/efectos adversos , Cirrosis Hepática/epidemiología , Cirrosis Hepática/terapia , Hepatopatías/terapia , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/terapia , Trasplante de Hígado , Lopinavir/efectos adversos , Enfermedad del Hígado Graso no Alcohólico/epidemiología , Enfermedad del Hígado Graso no Alcohólico/terapia , Pandemias/prevención & control , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/prevención & control , Purinas , Pirazinas/efectos adversos , Pirazoles , Ritonavir/efectos adversos , SARS-CoV-2 , Arabia Saudita/epidemiología , Sulfonamidas/efectos adversos , Ultrasonografía/métodos , Tratamiento Farmacológico de COVID-19
4.
Obes Surg ; 29(5): 1694-1696, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30826913

RESUMEN

Intragastric balloon (IGB) placement for the treatment of obesity has been in use for more than three decades. The major advantage of IGBs is that they preserve the anatomy of the stomach and are generally considered safe; the most common complications are nausea/vomiting and abdominal pain, and very rarely are IGBs associated with mortality (0.05%). A total of 14 cases of pancreatitis complicating IGBs have been reported in the literature. In this series, we reported 10 patients who developed acute pancreatitis in association with IGBs of which half were treated conservatively without the removal of the IGBs.


Asunto(s)
Balón Gástrico/efectos adversos , Pancreatitis/etiología , Pancreatitis/terapia , Adulto , Analgésicos/uso terapéutico , Remoción de Dispositivos , Femenino , Fluidoterapia , Humanos , Masculino , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...